Mental health outcomes following a psilocybin session within Oregon's state-regulated model: A naturalistic study

This naturalistic study of 88 adults in Oregon's state-regulated psilocybin program found that sessions resulted in significant, clinically meaningful improvements in depression, anxiety, and well-being at 30 days post-session, with no persistent adverse events reported.

The Gist

Imagine the state of Oregon as a pioneer explorer who just opened a new, regulated "mental health garden." In 2020, they became the first place in the U.S. to legally allow adults to visit this garden and use a specific, naturally grown plant (magic mushrooms) to help with their emotional struggles, without needing a doctor's prescription.

But here was the big question: Did it actually work in the real world?

Until now, we only knew if these mushrooms worked in super-controlled "laboratory greenhouses" where scientists picked very specific people and gave them synthetic chemicals. We didn't know what happened when regular people, with messy real lives and complex medical histories, went to a licensed center in Oregon.

This study is like a field report from that garden. Here is what the researchers found, explained simply:

1. The Experiment: A "Real-World" Test Drive

The researchers followed 88 people who visited a licensed center called "Bendable Therapy" in Oregon between 2024 and 2025.

• The Participants: These weren't just healthy volunteers. They were regular people, many of whom were already taking medication for depression or anxiety, had PTSD, or had tried psychedelics before. They were diverse in age and background.
• The Process: Think of the experience like a guided journey.
  • Preparation: Before the trip, they had meetings to get ready (like packing a bag and checking the weather).
  • The Journey: They sat in a comfortable room with a trained guide (facilitator) and consumed a measured amount of mushroom tea or whole mushrooms.
  • Integration: Afterward, they had more meetings to process what happened (like unpacking the bag and making sense of the view).

2. The Results: A Brighter Horizon

The researchers checked in with these people 30 days after their journey. They used three simple "thermometers" to measure how people felt:

• Depression Thermometer (PHQ-8): How heavy does the world feel?
• Anxiety Thermometer (GAD-7): How jittery or worried are you?
• Well-being Thermometer (WHO-5): How happy and energetic do you feel?

The Verdict: The results were like a sunrise after a long, dark night.

• Depression and Anxiety: Both dropped significantly. It's as if the heavy blanket of sadness and the constant buzzing of worry were lifted.
• Well-being: This score jumped up dramatically. People didn't just feel "less sad"; they felt more alive, more resilient, and more capable of handling life's curveballs.
• The "Medication" Factor: Even people who were still taking their daily antidepressants or anxiety meds saw these huge improvements. It's like the mushrooms worked alongside their existing support, not by replacing it.

3. The Safety Check: Did the Garden Have Thorns?

Whenever you try something new, you worry about side effects.

• The "Trip" Hangover: A few people reported some weird visual glitches (like seeing trails when moving objects) the day after, similar to a mild hangover. However, by the 30-day mark, almost everyone was back to normal.
• Distress: Only a tiny fraction (2 out of 88) felt significant distress that lasted.
• The Takeaway: The "garden" was surprisingly safe. The strict rules and the presence of trained guides acted like a safety net, catching people before they fell too hard.

4. The Dosage: Not "More" is Better

In the past, people thought you needed a huge dose to get results. This study found that the average dose people took was about 28 mg (a moderate amount).

• The Analogy: It's like tuning a radio. You don't need to blast the volume to the maximum to hear the music clearly. A moderate, well-calibrated dose was enough to get the signal, and it was safer than taking a massive dose.

5. Why This Matters (The Big Picture)

Think of this study as the first successful test flight of a new airline.

• Before: We only knew the plane could fly in a wind tunnel (clinical trials).
• Now: We know it can fly with real passengers, in real weather, carrying people with all kinds of luggage (complex mental health issues).

The Conclusion:
Oregon's new model proves that psilocybin therapy isn't just a science experiment; it can be a safe, effective, and accessible tool for regular people. It suggests that with the right guides, the right rules, and a supportive environment, we can help people heal from deep emotional wounds in a way that feels natural and human.

In short: The "magic mushrooms" in Oregon's legal garden worked. They helped people feel less sad, less worried, and more alive, proving that this ancient remedy, when used carefully in the modern world, has a bright future.

Technical Summary

1. Problem Statement

While psilocybin has shown promise in controlled clinical trials for treating depression and anxiety, there is a significant gap in understanding its effectiveness in real-world, community-based settings.

• Context: In 2020, Oregon became the first U.S. state to establish a regulated framework (Measure 109) allowing adults to access naturally derived psilocybin services without a medical diagnosis or prescription.
• The Gap: Previous clinical trials often exclude individuals with complex psychiatric histories or concurrent psychiatric medication use and utilize synthetic psilocybin under strict protocols. Conversely, aggregate data from Oregon's regulatory body lacks clinical outcome measures. There is a need to evaluate the therapeutic effectiveness, safety, and dosing patterns of psilocybin services delivered under this unique, non-medical, state-regulated model using natural mushroom products.

2. Methodology

Study Design:

• Type: Prospective, naturalistic observational study.
• Setting: Integrated into "Bendable Therapy," a licensed psilocybin service center in Bend, Oregon, operating under Oregon Health Authority (OHA) regulations.
• Timeline: March 2024 – April 2025.
• Participants: $N=88$ adults (aged 21+).
  • Demographics: Median age 43; 52% male; 87.5% White; 53.4% Oregon residents.
  • Clinical Profile: 51.1% reported depression, 42.0% anxiety, 19.3% PTSD. 46.6% were concurrently using psychiatric medications. 64.8% had prior psychedelic experience.
• Intervention:
  • Participants underwent a structured protocol including screening, preparation, and a supervised psilocybin administration session (individual or group).
  • Dosing: Psilocybin was consumed as whole mushrooms or tea. Dosing followed a protocol of 20–30 mg Total Psilocybin Equivalents (TPE), with optional boosters.
  • Dose Calculation: Doses were calculated as TPE (Total Psilocybin Equivalents) = Psilocybin (mg) + 1.39 × Psilocin (mg), accounting for the conversion of psilocybin to its active metabolite.
• Measures:
  • Primary Outcomes: Changes in depression (PHQ-8), anxiety (GAD-7), and well-being (WHO-5) from pre-session to 30-days post-session.
  • Safety: Assessment of adverse events, specifically Hallucinogen Persisting Perception Disorder (HPPD) and lingering negative psychological effects, at 1-day and 30-days post-session.
  • Statistical Analysis: Linear mixed-effects models (LMM) with random intercepts for participants and fixed effects for timepoint, sex, age, medication use, and dose. Effect sizes calculated using Cohen's $d$.

3. Key Contributions

• First Real-World Evaluation: This is the first study to systematically evaluate mental health outcomes within Oregon's state-regulated psilocybin model, bridging the gap between controlled efficacy trials and real-world effectiveness.
• Inclusive Population: Unlike many trials, this study included participants with complex psychiatric comorbidities and those actively taking psychiatric medications, providing data on a population often excluded from research.
• Natural Product Quantification: The study utilized a rigorous dosing metric (TPE) that accounts for both psilocybin and psilocin content in naturally derived whole-mushroom products, offering a framework for future regulatory dosing standards.
• Safety Data: It provides early safety data on HPPD and adverse events in a regulated, facilitated setting using natural products.

4. Key Results

Mental Health Outcomes (30-Day Follow-up):

• Depression (PHQ-8): Significant reduction in scores ($\Delta = -4.63$, $p < 0.001$). Effect size was large ($d = 0.90$).
• Anxiety (GAD-7): Significant reduction in scores ($\Delta = -4.85$, $p < 0.001$). Effect size was large ($d = 1.04$).
• Well-being (WHO-5): Significant improvement in scores ($\Delta = +10.67$, $p < 0.001$). Effect size was very large ($d = -2.14$).
• Medication Subgroup: Sensitivity analyses confirmed that significant improvements were observed in both participants taking psychiatric medications and those who were not ($p < 0.001$ for all outcomes in both groups).

Dosing and Predictors:

• Mean Dose: 27.8 mg TPE (SD 8.2); 24.3 mg pure psilocybin (SD 8.3).
• Predictors: The only significant predictor of higher administered dose was concurrent use of psychiatric medications (participants on meds received an average of 29.6 mg TPE vs. 26.2 mg TPE for others).

Safety and Adverse Events:

• HPPD: 39.7% reported transient HPPD-like symptoms at 1-day; however, only 2.3% reported symptoms causing significant distress. By 30 days, no participants reported distressing HPPD symptoms.
• Lingering Negative Effects: 3.4% of participants reported lingering negative effects (e.g., anxiety, existential struggle) at 30 days.
• Retention: High retention rate with only 3 participants excluded from the final analysis.

5. Significance and Implications

• Therapeutic Efficacy: The study demonstrates that psilocybin services delivered under Oregon's regulatory model produce clinically meaningful and statistically significant improvements in depression, anxiety, and well-being within 30 days.
• Safety Profile: The low incidence of persistent adverse events (specifically HPPD) in a facilitated, naturalistic setting suggests that regulated access with professional support is safe, even for individuals with complex mental health histories.
• Policy Impact: The findings support the viability of Oregon's non-medical model. They suggest that lower average doses (under 30 mg TPE) may be effective, potentially informing future policy on maximum dose limits (currently capped at 50 mg).
• Medication Compatibility: The results challenge the assumption that psychiatric medications blunt psilocybin's effects, showing that concurrent medication use did not prevent therapeutic gains, though further controlled research is needed to confirm this interaction.
• Future Directions: The study highlights the need for longer-term follow-up (>30 days) and research in more diverse populations to fully characterize the long-term sustainability of these benefits.

Conclusion:
This study provides critical translational evidence that psilocybin services, when delivered within a structured, supportive, and regulated framework using natural products, can effectively improve mental health outcomes for a diverse community-based population, including those with complex psychiatric histories and concurrent medication use.